Indian medicinal plant Acanthus ilicifolius may combat liver cancerJanuary 17, 2008Liver cancer is the fifth most common cancer in the world with a poor prognosis. About three quarters of the cases of liver cancer are found in Southeast Asia, including China, Hong Kong, Taiwan, Korea, India, and Japan. The frequency of liver cancer in Southeast Asia and sub-Saharan Africa is greater than 20 cases per 100,000 population. Moreover, recent data show the frequency of liver cancer in the U.S. overall is rising. With the increasing trend in the incidence of cancers in our country, biomedical research directed at early detection and diagnosis, prognosis and survival, as well as prevention of progression of malignancy, is of prime importance. The aim of cancer chemoprevention is to circumvent the development and progression of malignant cells through the use of non-cytotoxic nutrients, herbal preparations/natural plant products, and/or pharmacological agents. Encouraging dietary intake with herbal supplements may therefore be an effective strategy to limit DNA lesions and organic injuries leading to cancers and other chronic degenerative diseases. A research article published in the December 28 issue of the World Journal of Gastroenterology explores this point. A research article published on December 28, 2007 in the World Journal of Gastroenterology (volume 13, issue 48) addresses this problem. The research team led by Prof. Malay Chatterjee from Jadavpur University investigated the primary chemopreventive mechanisms of Acanthus ilicifolius in an in vivo tumor-transplanted murine model. A. ilicifolius, popularly known as ¡°Harkach Kanta¡± is distributed widely throughout the mangroves of India, including Sunderbans in West Bengal, west coasts, and the Andamans, and in other Asian countries like Singhal, Burma, China, Thailand etc. The results showed the aqueous leaf extract (ALE) of the plant was substantially effective in preventing hepatic DNA alterations and sister-chromatid exchanges (a type of chromosomal damage) in tumor-bearing mice. The study further demonstrated that ALE treatment was able to limit liver metallothionein expression, a potential marker for cell proliferation, and lengthen the mean survival of animals to a significant extent. The findings suggest that A. ilicifolius may be used as a potential chemoprotector against hepatic neoplasia. This research from Prof. Chatterjee¡-s laboratory opens up a promising avenue in cancer chemoprevention with the use of indigenous plants. The results obtained from this in vivo study seem interesting and encouraging. Lack of toxicity favors further preclinical evaluation of A. ilicifolius in a defined chemical carcinogenesis model. Elucidation of its anticarcinogenic mechanisms of action at the intricate molecular circuits, and isolation and characterization of its active principles, will provide a better understanding of the anti-cancer/chemoprevention strategy of A. ilicifolius. If these studies are found to be really functional, we will have the beginning of a new chemoprevention program with herbal supplements that could have the broadest implications for the well-being of society. World Journal of Gastroenterology |
|||||||||||||||||||||
| Related Liver Cancer Current Events and Liver Cancer News Articles Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Toward explaining why hepatitis B hits men harder than women Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Largest-ever database for liver proteins may lead to treatments for hepatitis Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ. 1 disease, not 1 demographic The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander." Parasite growth hormone pushes human cells to liver cancer Scientists have found that the human liver fluke (Opisthorchis viverrini) contributes to the development of bile duct (liver) cancer by secreting granulin, a growth hormone that is known to cause uncontrolled growth of cells. Certain cancers more common among HIV patients than non-HIV patients Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s. Discovery could improve hepatitis C treatment Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments. Sorafenib significantly improves the length of time before breast cancer worsens ne of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening. Penn State College of Medicine research isolates liver cancer stem cells prior to tumor formation Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer. New biomarker predicts response to hepatitis C treatment Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference. More Liver Cancer Current Events and Liver Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||